Monograph

D10AX03 - Azelaic Acid

Possibly porphyrinogenic

Rationale

Endogenous organic acid with significant systemic exposure in dermal use

Chemical description

Azelaic acid, endogenous antibacterial substance in creme 200 mg mg / g for dermal use twice daily in acne of moderate severity. Less than 5 % is absorbed through the skin. Urinary excretion is stated to be 25 mg/24 h.

IPNet drug reports

Uneventful use reported in 1 patient with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes D10A / D10AX or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Belgium